Related Experiment Video

Updated: Jun 4, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Monoclonal antibodies for medical oncology: a few critical perspectives

Cristóbal Belda-Iniesta1, Inmaculada Ibáñez de Cáceres, Javier de Castro

  • 1Biomarkers and Experimental Therapeutics Group, IdiPAZ, University Hospital La Paz, Madrid, Spain. cbelda.hulp@salud.madrid.org

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|February 18, 2011
PubMed

Insights

Antibodies, particularly monoclonal antibodies (mAbs), are revolutionizing cancer therapy, improving patient survival and response rates across various cancers. Future antibody-based treatments promise further advancements in oncology.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Antibody-based therapies have significantly improved outcomes for cancer patients.
  • These therapies are effective against solid tumors like breast, lung, and colon cancer, as well as hematological malignancies.

Purpose of the Study:

  • To review current indications for monoclonal antibodies (mAbs) in solid tumor treatment.
  • To introduce emerging antibody-based therapies for future clinical application.

Main Methods:

  • Literature review of current and emerging monoclonal antibody applications in oncology.
  • Discussion of clinical and radiological response data associated with antibody therapy.

Main Results:

  • Monoclonal antibodies demonstrate efficacy as standalone or combination treatments.
  • Significant improvements in patient survival and response rates observed with antibody therapy.

Conclusions:

  • Monoclonal antibodies are indispensable tools in modern cancer treatment.
  • Future developments in antibody therapeutics, including novel mAbs and protein-based drugs, are anticipated to expand treatment options.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...